Curium | Jotup

Curium Announces First Commercial Doses in Germany of PYLCLARI® – An Innovative 18F-PSMA PET Tracer Indicated in Patients With Prostate Cancer

Retrieved on:

Montag, Mai 6, 2024

Curium, PSMA, FDA, Cancer, Prostate, Food, Nuclear medicine, PET, Prostate cancer, European, INN, Patient, Physician, Medical imaging

PARIS, May 06, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced that today in Munich and Nurnberg, Germany the first commercial doses of PYLCLARI® have been delivered.

Key Points:

PARIS, May 06, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced that today in Munich and Nurnberg, Germany the first commercial doses of PYLCLARI® have been delivered.
With today’s announcement, we are extremely proud to be improving the choice of diagnostic modalities available to our customers in Germany – ultimately for the benefit of patients with prostate cancer.”
In Germany, prostate cancer is the most common cancer among men with around 63,400 new cases diagnosed nationwide every year.
Today’s announcement is part of the continued roll-out of PYLCLARI® across the European Union, which is now available for patients with prostate cancer in Greece, Italy, and the Netherlands.
In the U.S., Lantheus received approval for PYLARIFY® (Piflufolastat (18F) Injection) from the Food and Drug Administration (FDA) in May 2021.

Curium Enrolls First Prostate Cancer Patients in its Phase 3 SOLAR Trials

Retrieved on:

Dienstag, April 23, 2024

Curium, Copper, Clinical trial, Cancer, SOLAR, Nuclear medicine, Recurrence, MD, Prostate cancer, Patient, Google Images, Medical imaging

The second study, SOLAR-RECUR: a Phase 3, multicenter, open-label study to evaluate the diagnostic performance of copper Cu 64 PSMA I&T PET/CT in men with suspected biochemical recurrence of prostate cancer after radical prostatectomy or radiation therapy.

Key Points:

The second study, SOLAR-RECUR: a Phase 3, multicenter, open-label study to evaluate the diagnostic performance of copper Cu 64 PSMA I&T PET/CT in men with suspected biochemical recurrence of prostate cancer after radical prostatectomy or radiation therapy.
These clinical trials are currently enrolling patients at sites across the U.S. and will be opening clinical trial sites in Europe later this year.
Sakir Mutevelic, MD, Curium’s Chief Medical Officer said: “The successful start of patient enrollment is a significant step forward for Curium’s Phase 3 SOLAR-STAGE and SOLAR-RECUR clinical trials.
We are pleased to announce the first patients enrolled and scanned were at XCancer® under the direction of Dr. Luke Nordquist.

Curium Announces First Commercial Dose in the Netherlands of PYLCLARI® – an Innovative 18F-PSMA PET Tracer Indicated in Patients With Prostate Cancer

Retrieved on:

Dienstag, April 9, 2024

Curium, Civil service commission, Prostate cancer, Patient, PET, News, INN, Cancer, Prostate, European, European Commission, FDA, Nuclear medicine, Physician, PSMA, Food, Medical imaging

PARIS, April 09, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced that today in the Netherlands the first commercial dose of PYLCLARI® has been sold.

Key Points:

PARIS, April 09, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced that today in the Netherlands the first commercial dose of PYLCLARI® has been sold.
In the U.S., Lantheus received approval for PYLARIFY® (Piflufolastat F 18 Injection) from the Food and Drug Administration (FDA) in May 2021.
It is the #1 utilized PSMA PET agent in the U.S. market.
The European rights were licensed by Curium from Progenics, a Lantheus company, in 2018.

Radiopharmaceuticals Market to Reach $11.6 Billion by 2034 as Cancer Treatment Gains Traction - Future Market Insights, Inc.

Retrieved on:

Montag, März 25, 2024

Curium, FMI, Novartis, Eli Lilly, Face, FAP, Associate, Hospital, Bayer, Cancer, Actinium-225, Medicare, Radiopharmaceutical, Radio, Therapy, Eli Lilly and Company, Government

NEWARK, Del., March 25, 2024 /PRNewswire/ -- Radiopharmaceuticals is one of the most effective and newly emerged cancer treatment methodologies, which is gaining popularity in the medicare sector worldwide. With the current valuation of US$ 6,972.1 million, the Radiopharmaceuticals market is very likely to have a promising future in the coming decade. Rising incidences of cancer and cancer-associated diseases are one of the main reasons for that.

Key Points:

This report by FMI dives deep into why this market is thriving, what bumps it might face, and the exciting possibilities ahead.
NEWARK, Del., March 25, 2024 /PRNewswire/ -- Radiopharmaceuticals is one of the most effective and newly emerged cancer treatment methodologies, which is gaining popularity in the medicare sector worldwide.
With the current valuation of US$ 6,972.1 million, the Radiopharmaceuticals market is very likely to have a promising future in the coming decade.
Although the market is still in its nascent stages, it is slated to pick up some pace in the coming decade.

Curium Announces First Commercial Doses in Italy of PYLCLARI® – An Innovative 18F-PSMA PET Tracer Indicated in Patients With Prostate Cancer

Retrieved on:

Donnerstag, März 7, 2024

Curium, European Commission, Physician, FDA, Food, PSMA, Prostate, INN, European, Civil service commission, Patient, Nuclear medicine, PET, Cancer, Prostate cancer, Medical imaging

PARIS, March 07, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today that the first commercial doses of PYLCLARI® have been sold in Italy.

Key Points:

PARIS, March 07, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today that the first commercial doses of PYLCLARI® have been sold in Italy.
Today’s announcement follows the decision in July 2023 by the European Commission granting marketing authorization for PYLCLARI® in the European Union.
On 3rd February 2024 The Italian Medicines Agency (Agenzia Italiana del Farmaco) published the decision for PYLCLARI® in Italy.
The European rights were licensed by Curium from Progenics, a Lantheus company, in 2018.

Curasight announces acceleration of therapeutic strategy to strengthen position as a radiopharmaceutical theranostic company

Retrieved on:

Dienstag, Februar 13, 2024

COPENHAGEN, Denmark, Feb. 13, 2024 /PRNewswire/ -- Curasight A/S ("Curasight" or the "Company" (XSAT: CURAS) announces today that it is accelerating and expanding its clinical therapeutic strategy with the addition of a new Phase I/IIa trial to include a total of five cancer indications in a so called basket trial design.

Key Points:

COPENHAGEN, Denmark, Feb. 13, 2024 /PRNewswire/ -- Curasight A/S ("Curasight" or the "Company" (XSAT: CURAS) announces today that it is accelerating and expanding its clinical therapeutic strategy with the addition of a new Phase I/IIa trial to include a total of five cancer indications in a so called basket trial design.
To strengthen the Company's capital structure and secure funding for the acceleration of clinical activities, Curasight intends to launch a rights issue during the first quarter of 2024.
By launching this basket trial, we can accelerate development of both uTRACE and uTREAT (theranostic) in parallel and potentially have therapeutic efficacy data already during 2025.
Under the terms of the deal, Curasight is responsible for development until regulatory approval with Curium responsible for manufacturing and commercialisation.

Curasight announces acceleration of therapeutic strategy to strengthen position as a radiopharmaceutical theranostic company

Retrieved on:

Dienstag, Februar 13, 2024

COPENHAGEN, Denmark, Feb. 13, 2024 /PRNewswire/ -- Curasight A/S ("Curasight" or the "Company" (XSAT: CURAS) announces today that it is accelerating and expanding its clinical therapeutic strategy with the addition of a new Phase I/IIa trial to include a total of five cancer indications in a so called basket trial design.

Key Points:

COPENHAGEN, Denmark, Feb. 13, 2024 /PRNewswire/ -- Curasight A/S ("Curasight" or the "Company" (XSAT: CURAS) announces today that it is accelerating and expanding its clinical therapeutic strategy with the addition of a new Phase I/IIa trial to include a total of five cancer indications in a so called basket trial design.
To strengthen the Company's capital structure and secure funding for the acceleration of clinical activities, Curasight intends to launch a rights issue during the first quarter of 2024.
By launching this basket trial, we can accelerate development of both uTRACE and uTREAT (theranostic) in parallel and potentially have therapeutic efficacy data already during 2025.
Under the terms of the deal, Curasight is responsible for development until regulatory approval with Curium responsible for manufacturing and commercialisation.

Curasight A/S Achieves First Milestone under collaboration with Curium Inc.

Retrieved on:

Montag, Januar 22, 2024

Curium, Prostate cancer, Receptor (biochemistry), Nuclear medicine, GMP, USD, News, Diagnosis, Pharmaceutical industry

USD 500.000 payment is the first milestone under the global license and collaboration agreement for the development and commercialization of uTRACE® for use in prostate cancer between Curasight A/S and Curium Inc.

Key Points:

USD 500.000 payment is the first milestone under the global license and collaboration agreement for the development and commercialization of uTRACE® for use in prostate cancer between Curasight A/S and Curium Inc.
COPENHAGEN, Jan. 22, 2024 /PRNewswire/ -- Curasight A/S ("Curasight" or "the Company") – (TICKER: CURAS) today announced the achievement of the first milestone under the agreement with Curium inc., to develop Curasight's uTRACE® PET imaging technology for the improved diagnosis of prostate cancer.
The milestone relates to the validation of GMP manufacturing of finished product.
The USD 500.000 milestone is the first in the agreement signed with Curium Inc. in May 2023.
Curasight is eligible to receive up to mUSD 70 in development and commercial milestones as well as double-digit percentage royalties on sales in major markets upon eventual commercialization.

Curasight A/S Achieves First Milestone under collaboration with Curium Inc.

Retrieved on:

Montag, Januar 22, 2024

Curium, Prostate cancer, Receptor (biochemistry), Nuclear medicine, GMP, USD, News, Diagnosis, Pharmaceutical industry

USD 500.000 payment is the first milestone under the global license and collaboration agreement for the development and commercialization of uTRACE® for use in prostate cancer between Curasight A/S and Curium Inc.

Key Points:

USD 500.000 payment is the first milestone under the global license and collaboration agreement for the development and commercialization of uTRACE® for use in prostate cancer between Curasight A/S and Curium Inc.
COPENHAGEN, Jan. 22, 2024 /PRNewswire/ -- Curasight A/S ("Curasight" or "the Company") – (TICKER: CURAS) today announced the achievement of the first milestone under the agreement with Curium inc., to develop Curasight's uTRACE® PET imaging technology for the improved diagnosis of prostate cancer.
The milestone relates to the validation of GMP manufacturing of finished product.
The USD 500.000 milestone is the first in the agreement signed with Curium Inc. in May 2023.
Curasight is eligible to receive up to mUSD 70 in development and commercial milestones as well as double-digit percentage royalties on sales in major markets upon eventual commercialization.

Curium Completes Patient Enrollment of Phase 3 ECLIPSE Trial Ahead of Schedule

Retrieved on:

Donnerstag, November 23, 2023

Curium, Oncology, Physician, Master of Science, Nuclear medicine, Prostate cancer, MD, Patient, Safety, Urology, Radiation, Pharmaceutical industry

ST. LOUIS, Nov. 23, 2023 (GLOBE NEWSWIRE) -- Curium, a global leader in nuclear medicine, announced today the successful completion of patient enrollment in the pivotal Phase 3 ECLIPSE trial.

Key Points:

ST. LOUIS, Nov. 23, 2023 (GLOBE NEWSWIRE) -- Curium, a global leader in nuclear medicine, announced today the successful completion of patient enrollment in the pivotal Phase 3 ECLIPSE trial.
ECLIPSE is a Phase 3, multi-center, open-label, randomized clinical trial comparing the safety and efficacy of 177Lu-PSMA I&T versus hormone therapy in patients with metastatic castration-resistant prostate cancer.
The ECLIPSE trial enrolled over 400 patients, ahead of schedule, across 51 trial sites in the United States and Europe.
Sakir Mutevelic, MD, MSc, Chief Medical Officer at Curium said: “We are proud to announce the completion of enrollment in the ECLIPSE trial, and would like to thank the patients, trial investigators, clinical research partners and our Curium cross-functional teams for their dedication and commitment.